FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	e: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Street)	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET (Street) PETACH TIKVA L3 4951033					2. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA] 3. Date of Earliest Transaction (Month/Day/Year) 02/09/2018 4. If Amendment, Date of Original Filed (Month/Day/Year)							6. I	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Exec. VP, European Commercial 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
4 Tido of	Saarwite (Inc		le I - N					Acc	quired, D	isp						6.0	wnership	7. Nature	
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Execution Date,					ities Acquired (A) o d Of (D) (Instr. 3, 4		Securit Benefic Owned	es For		n: Direct or rect (I)	of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)					tr. 4)	(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/	n Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable an Expiration Date (Month/Day/Year)		В	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is Illy	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Stock Options (right to buy)	\$18.61	02/09/2018			A		100,457		(1)	02	2/08/2028	Ordinary Shares ⁽²⁾	100,457	\$0.00	100,45	7	D		
Restricted Share Units	(3)	02/09/2018			A		39,405		(4)		(4)	Ordinary Shares ⁽²⁾	39,405	\$0.00	39,405	5	D		

Explanation of Responses:

- 1. Stock options were granted on February 9, 2018, with 33,485 vesting on each of February 9, 2020 and February 9, 2021 and 33,487 vesting on February 9, 2022.
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 3. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- 4. Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

Remarks:

/s/ Dov Bergwerk as attorney-

02/12/2018

in-fact for Richard Daniell

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.